Agilent receives expanded fda approval for pd-l1 ihc 22c3 pharmdx in triple-negative breast cancer

Santa clara, calif.--(business wire)--agilent technologies inc. (nyse: a) today announced it has received fda approval for the use of pd-l1 ihc 22c3 pharmdx as an aid in identifying patients with triple-negative breast cancer (tnbc) for treatment with keytruda® (pembrolizumab). pd-l1 expression is a critical biomarker for response to anti-pd-1 therapies such as keytruda. the expanded use of pd-l1 ihc 22c3 pharmdx strengthens the ability of pathologists to identify patients who may be eligible f
A Ratings Summary
A Quant Ranking